Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BD0801 (Sevacizumab) plus chemotherapy versus placebo plus chemotherapy in platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer
CTR20210585Phase 3Active
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of suvemcitug in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Simcere Pharmaceutical Group. Started Jun 2021; status: active.
02
Drugs
suvemcitug
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20210585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210585.